Introduction {#sec1_1}
============

Apolipoprotein E2 (*apoE2*; Arg158Cys) homozygotes account for more than 90% of all cases of type III hyperlipoproteinemia (HLP) \[[@B1]\]. Although *apoE2* homozygotes comprise 0.5% of the Japanese population \[[@B2]\] and 0.6--1% of the Caucasian population \[[@B3]\], most (95%) of them are normolipidemic or even hypolipidemic due to low low-density lipoprotein (LDL) cholesterol levels as a result of a compensatory upregulated expression of LDL receptors \[[@B1]\]. Only a minority of *apoE2* homozygotes develop type III HLP. The presence of additional genetic, hormonal or environmental factors, such as diabetes mellitus, decreased LDL receptor activity, hypothyroidism, hyperinsulinemia, obesity, menopause, or *apoC3* or *apoA5* mutations \[[@B1], [@B3]\], is required for the development of type III HLP. Moreover, glomerulonephropathy in HLP \[[@B4], [@B5]\] or *apoE2* homozygotes \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11]\], which is characterized by foam cell infiltration in the glomeruli, is very rarely reported, whereas over 100 cases of lipoprotein glomerulopathy (LPG) were found on the PubMed database. LPG is characterized by lipid thrombi in the dilated glomerular capillaries, and patients with LPG are usually harboring various mutations in the *apoE* gene \[[@B12]\]. The frequency of *apoE2* homozygotes is 0.5--1% in the general population and may be much higher than the frequency of *apoE* variants associated with LPG, such as *apoE*-Sendai (Arg145Pro), *apoE*-Kyoto (Cys25Arg) and *apoE*-Tokyo (Leu141 to Lys143del) \[[@B12]\]. We herein report 3 cases of *apoE2* homozygous glomerulopathy diagnosed by renal biopsy and DNA analysis. All 3 patients showed foam cell infiltration in the glomeruli and had a single nucleotide substitution of cysteine for arginine at codon 158 (Arg158Cys) of the *apoE* gene without other mutations.

Case Report {#sec1_2}
===========

Case 1 {#sec2_1}
------

A 66-year-old male was referred to our center by his primary care physician because of the increase of proteinuria. He was diagnosed with diabetes at the age of 50 years but remained untreated. At the age of 60 years, he started voglibose at the diabetes center of our hospital. At the age of 66 years, urinary abnormality of protein 3+ and occult blood 1+ was pointed out, combined with simple diabetic retinopathy and a serum creatinine level of 0.96 mg/dl. He was referred to our center for further investigation, and a renal biopsy was performed. One of 11 glomeruli showed global sclerosis, and the other glomeruli showed massive foam cell infiltration in the glomerular capillaries and mildly expanded mesangium (fig. [1a](#F1){ref-type="fig"}). These foam cells immunohistochemically stained positive for cluster differentiation 68 (CD68) (not shown). Transmission electron microscope images also revealed foam cell infiltration mainly located in the capillaries containing scattered lipid droplets and lamellar bodies in their cytoplasm (fig. [1d](#F1){ref-type="fig"}). The glomerular basement membrane (GBM) showed mild thickening, and nodular lesions were formed in some glomeruli. The interstitium and tubules showed mild fibrosis and atrophy (25% of the cortical region), and a moderate degree of arteriolar hyalinosis was also found. No interstitial foamy cells or foamy tubular degeneration was found. Immunofluorescence study revealed no significant glomerular deposits. The patient\'s lipid profile showed type III HLP (table [1](#T1){ref-type="table"}). Apolipoprotein phenotype analysis showed a homozygosity of apoE2. A further DNA sequence analysis was performed as described previously \[[@B11]\] and showed a nucleotide substitution of cysteine for arginine at codon 158 (Arg158Cys) of the *apoE* gene and no other mutations. Eicosapentaenoic acid was added to his statin therapy, but he progressed to end-stage renal failure and was started on dialysis 8 years after the diagnosis.

Case 2 {#sec2_2}
------

A 58-year-old male was referred to our center by his primary care physician due to nephrotic syndrome. He had massive proteinuria (7.38 g/day) and hypoalbuminemia (1.9 g/dl). He had been treated for diabetes since the age of 50 years and had been started on insulin therapy at the age of 55 years. He had been well-managed (HbA1c, 5.3%), although a pre-proliferative retinopathy and mild renal dysfunction (sCr, 1.38 mg/dl) became evident. His renal biopsy revealed 5 of 22 glomeruli with global sclerosis. The residual glomeruli showed massive foam cell infiltration in the glomerular capillaries and severely widened mesangium (fig. [1b](#F1){ref-type="fig"}). These foam cells stained positive for CD68 (not shown). Transmission electron microscope images also revealed foam cell infiltration mainly located in the capillaries containing scattered lipid droplets and lamellar bodies in their cytoplasm (fig. [1e](#F1){ref-type="fig"}). The glomerular tufts were enlarged with hyalinosis, mesangiolysis and microaneurysmal formation, which were consistent with diabetic glomerulosclerosis. The interstitium and tubules showed moderate fibrosis and atrophy (50% of the cortical region). The foamy change was seen in some tubular epithelial cells, but no interstitial foamy cells were found. The interlobular arteries showed a moderate degree of fibrous intimal thickening, and the arterioles also showed a moderate degree of subendothelial hyalinosis. Immunofluorescence studies revealed nonspecific linear IgG deposits along the GBM; however, no significant deposit was found by electron microscopy. The patient\'s lipid profile showed type III HLP (table [1](#T1){ref-type="table"}). He had an *apoE*2 homozygote phenotype and the Arg158Cys genotype with no other mutations. Three years after the diagnosis, he progressed to renal failure and was started on hemodialysis.

Case 3 {#sec2_3}
------

A 78-year-old male with nephrotic syndrome was referred to our center by his primary care physician. The patient had a history of hypertension since the age of 45 years, hypothyroidism since the age of 68 years and diabetes mellitus since the age of 70 years. He also had a history of percutaneous coronary intervention for coronary artery disease and femoropopliteal bypass surgery for peripheral arterial disease at the age of 74 years, and a history of Wallenberg syndrome since the age of 77 years. He was being treated with an angiotensin II receptor blocker, a calcium-channel blocker, pitavastatin, aspirin and levothyroxine sodium hydrate. Diabetic control by diet and an oral α-glucosidase inhibitor were sufficient. There was no evidence of retinopathy or albuminuria before the episode of nephrosis. His urinalysis on admission was positive for proteinuria (2.5 g/day) and red blood cells (1--4/hpf). His blood chemistry findings were as follows: albumin 3.2 g/dl, creatinine 1.11 mg/dl and HbA1c 6.1%. A kidney biopsy revealed 21 glomeruli, of which 2 were globally sclerotic. The glomeruli showed increased mesangial matrices and mild GBM thickening. Massive foam cells had infiltrated into the glomerular capillaries and mesangial region (fig. [1c, g](#F1){ref-type="fig"}). These foam cells stained positive with Oil Red O (fig. [1h](#F1){ref-type="fig"}) and immunohistochemically stained positive for CD68 (fig. [1i](#F1){ref-type="fig"}). Transmission electron microscope images also revealed foam cell infiltration mainly located in the capillaries, and some mesangial cells showed scattered lipid droplets in their cytoplasm (fig. [1f](#F1){ref-type="fig"}). Mild interstitial fibrosis and tubular atrophy (20% of the cortical region) as well as moderate arteriosclerosis and arteriolar hyalinosis were found. The foamy change was seen in some tubular epithelial cells but no interstitial foamy cells were found. Immunofluorescence studies revealed segmental deposits of IgM and C3 in the mesangial area and slightly peripheral IgG deposits in the glomeruli; however, no significant deposit was found by electron microscopy. He had an *apoE*2 homozygote phenotype and the Arg158Cys genotype with no other mutations. After the diagnosis, ezetimibe was added to his statin therapy. The patient\'s most recent serum creatinine was increased to 2.1 mg/dl after 2 years.

Discussion {#sec1_3}
==========

Here, we report 3 cases of glomerulopathy with *apoE2* homozygosity. All 3 cases were 58-to 78-year-old elderly males with an at least 10-year history of diabetes. Their renal biopsies showed remarkable foam cell infiltration in the glomeruli accompanied with various degrees of glomerular abnormalities indicating diabetic nephropathy (DMN), such as mesangial expansion, GBM thickening, and nodular lesion formation. As glomerular foam cell infiltration is sometimes seen in DMN, it is difficult to differentiate between glomerulopathy with homozygous *apoE2* *(apoE2/2)* and DMN completely. However, the degree of foam cell infiltration in each case was unusually remarkable compared to that of ordinary DMN. The 3 cases had the *apoE2* homozygote phenotype and Arg158Cys genotype with no other mutations in common. Only 7 cases of glomerulopathy with *apoE2* homozygosity have been reported previously \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11]\], whereas over 100 cases of LPG have been reported (table [2](#T2){ref-type="table"}). All 7 cases showed nephrotic syndrome clinically, and 2 of them had diabetes \[[@B6], [@B9]\]. The fact that all of our 3 cases were elderly and had a 10-year history of diabetes suggests a possible role for diabetes in the development of *apoE2* homozygote glomerulopathy. However, what factors in the patients induced type III HLP or glomerular foam cell infiltration remains undetermined.

The histology of *apoE2* homozygote glomerulopathy is characterized by marked glomerular foam cell infiltration and is different from that of LPG, which shows lipoprotein thrombi with lamella formation in dilated glomerular capillaries. LPG seldom presents with massive foam cells infiltration in the glomeruli. One unusual case with LPG, a 54-year-old Japanese female, showed an *apoE2* homozygote phenotype \[[@B13]\]. In this case, the details of microscopic lamella formation in the lipid thrombi were unclear \[[@B13]\]. On the other hand, a previous report of siblings with *apoE2* homozygote glomerulopathy showed an unusual finding of glomerular lipoprotein thrombi and lipid particles \[[@B11]\]. The lamella formation in the lipid thrombi could not be detected on the electron microscopic images, however, suggesting that the ultrastructure of the lipid droplets in *apoE2* homozygote glomerulopathy is different from that in LPG. Regarding lipid-lowering treatment, 5 of the 7 previous cases were treated with fibrate \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11]\]. In our 3 cases, ezetimibe or eicosapentaenoic acid was combined with their ongoing statin therapies. The selection of these drugs was supported by the evidence that additional fibrate use in elderly people can be associated with serum creatinine elevation \[[@B14]\]. Conversely, repeated plasmapheresis using a dextran sulfate-cellulose column was effective in reducing proteinuria in a 59-year-old female with *apoE*2 homozygote glomerulopathy \[[@B6]\].

Concerning renal prognosis, prednisolone, FK-506 or cyclophosphamide could not prevent renal failure in a 12-year-old boy \[[@B8]\]; however, a 52-year-old male maintained normal renal function for 10 years despite massive proteinuria \[[@B11]\]. In 2 of our 3 cases, renal failure progressed 3 and 8 years after the diagnosis of kidney disease, and the third case also showed a gradual elevation of serum creatinine during the 2-year follow-up.

Etiologically, *apoE2* homozygosity and the other *apoE* mutations may be responsible for the development of the unique glomerulopathy both in LPG and *apoE*2 homozygote glomerulopathy. Patients with the *apoE2* homozygote phenotype also presented the glomerular lesions of LPG \[[@B13]\] or LPG-like lesions \[[@B11]\]. Similarly, the coexistence of homozygous *apoE2* and heterozygous *apoE* variants, such as *apoE*-Okayama (Arg150Gly) \[[@B15]\] and *apoE*-Modena (Arg150Cys) \[[@B16]\], has been reported in some cases with LPG. These reports are suggesting that a single mutation of *apoE*, or a combination of a certain *apoE* mutation and homozygous *apoE2*, may induce the functional abnormality of *apoE* synergistically and result in the unique form of lipid-related glomerulopathy, such as LPG and *apoE*2 homozygote glomerulopathy. Moreover, our cases are suggesting that diabetes is another contributing factor for the development of glomerulopathy. A previous report \[[@B17]\], showing *apoE2* as a risk factor for the progression of DMN in Japanese type 2 diabetes, also indicates a close association between DMN and lipid-related glomerulopathy.

In conclusion, *apoE2* homozygote glomerulopathy occurred in combination with DMN in our 3 elderly cases. We speculate that macrophage and lipid in addition to diabetes play a role in this unique lipid-related glomerulopathy. Further investigations are required to determine the pathogenesis of *apoE2* homozygote glomerulopathy and the clinical evidences for an appropriate therapeutic strategy.
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![Light and electron microscopic findings of the renal biopsy specimens. The glomeruli show massive foam cell infiltration mainly in the glomerular capillaries and partly in the mesangium (**a--g**). The foam cells are stained positive with Oil Red O (**h**) and are positive for CD68 by immunohistochemistry (**i**). Transmission electron microscope images reveal foam cells with lipid droplets or lamellar bodies mainly located in the capillaries (**d--f**), and some mesangial cells show scattered lipid droplets in their cytoplasm (**f**). Magnification in **b**, **d**, **f**: ×2,000. Signs for diabetic glomerulosclerosis, such as an increase of mesangial matrices (**b** \> **a**, **c**) and a thickening of the GBM, could be found to various degrees. **a**, **d** Case 1; **b**, **e** case 2; **c**, **f--i** case 3.](cru-0003-0128-g01){#F1}

###### 

Examinations at the time of admission

                                                                    Case 1   Case 2   Case 3
  ----------------------------------------------------------------- -------- -------- --------
  Age, years                                                        66       58       78
  Sex                                                               male     male     male
  Urinary protein, g/day                                            2.07     7.38     2.5
  Total protein, g/dl                                               6.4      3.9      6
  Albumin, g/dl                                                     3.5      1.9      3.6
  Serum creatinine, mg/dl                                           0.96     1.38     1.11
  HbA1c, %                                                          6.9      5.3      6.1
  Total cholesterol, mg/dl                                          221      253      287
  Triglyceride, mg/dl                                               437      194      389
  Lipoprotein electrophoresis, %[^a^](#T1F1){ref-type="table-fn"}                     
   HDL (22--47)                                                     20.3     14.4     27
   LDL (46--68)                                                     7.4      20.2     8
   IDL (0)                                                          46       41.5     46
   VLDL (3--19)                                                     26.3     23.9     19
  Apolipoproteins, mg/dl[^a^](#T1F1){ref-type="table-fn"}                             
   ApoA (119--155)                                                  92       112      156
   ApoB (7--109)                                                    74       79       65
   ApoE (2.7--4.3)                                                  11.4     10.7     9.9

Normal ranges for males are given in parentheses.

###### 

Features of glomerulopathy with homozygous apoE2

  Patient No.   Sex   Age, years   Protein-uria, g/day   sCr at diagnosis, mg/dl   Complications            Therapy                                  Renal prognosis after diagnosis   Athero-sclerosis   Ref.
  ------------- ----- ------------ --------------------- ------------------------- ------------------------ ---------------------------------------- --------------------------------- ------------------ ------------------------------------
  1             F     59           0.6--8.8              1.8                       DM, HT                   fibrate, colestyramine, plasmapheresis   sCr 2.2 mg/dl 2.5 years later     none               6
  2             F     00           3+ to 4+              0.3                       ND                       PSL, furosemide, metolazone              sCr 4.2 mg/dl 7.5 years later     none               7
  3             M     12           20.3                  1.1                       anemia                   RASI, PSL, CY, FK-506, statin→fibrate    renal failure 1.3 years later     none               8
  4             M     31           1.8--4.5              1.2                       DM, pan-creatitis        fibrate→statin                           ND                                none               9
  5             M     41           2.8--18.4             NR                        none                     PSL, CY, statin and fibrate              no progression 0.7 years later    none               10
  6             M     52           3.0--7.5              0.8                       none                     PSL, aspirin                             no progression for 10 years       none               11
  7             F     49           2.0--4.0              0.5                       HT                       fibrate                                  no progression for 2 years        none               11
  8             M     64           1.6--2.1              0.9                       DM                       RASI, statin, EPA                        HD induction 8 years later        CAD                [^\*^](#T2F1){ref-type="table-fn"}
  9             M     58           5.0--8.8              1.6                       DM, HT                   RASI, statin, EPA                        HD induction 3 years later        none               [^\*^](#T2F1){ref-type="table-fn"}
  10            M     78           1.9--4.2              1.1                       DM, HT, hypothyroidism   RSI, statin, ezetimibe                   sCR 2.1 mg/dl 2 years later       CAD, CI, PAD       [^\*^](#T2F1){ref-type="table-fn"}

CAD = Coronary artery disease; CI = cerebral infarction; CY = cyclophosphamide; DM = diabetic mellitus; EPA = eicosapentaenoic acid; HD = hemodialysis; HT = hypertension; ND = not described; NR = within the normal range; PAD = peripheral arterial disease; PSL = prednisolone; RASI = renin-angiotensin system inhibitor; sCr = serum creatinine.

Current cases.
